Answer
Maribavir (Livtencity) is not expected to treat CMV central nervous system infections effectively because nonclinical data predict low CNS penetration compared with plasma levels, and it has not been studied in patients with CMV CNS infection.
Sources for this answer
- LIVTENCITY 200 mg film coated tabletsTakeda UK Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 5Document updated
Sources checked